Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | SIRT6 | Q8N6T7 | 7/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 4/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23124217 | 0.90 | SIRT6 (0.58) | HPGDSIRT6MAPTALDH1A1MAPK1 | |
| SCHEMBL22652220 | 0.90 | HPGD (0.68) | HPGDSIRT6MAPTALDH1A1MAPK1 | |
| SCHEMBL170932 | 0.87 | HPGD (0.75) | HPGDSIRT6MAPTALDH1A1MAPK1 | |
| SCHEMBL13395270 | 0.86 | SIRT6 (0.54) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL29173187 | 0.84 | SIRT6 (0.52) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL375616 | 0.84 | SIRT6 (0.77) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL27913615 | 0.82 | HPGD (0.65) | HPGDMAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL2825492 | 0.82 | MAPT (0.67) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL14866270 | 0.82 | SIRT6 (0.59) | SIRT6MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL29287538 | 0.81 | HPGD (0.71) | HPGDSIRT6MAPTALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-04-18 | — | — | US | disclosed |
| US-8318702-B2 | Di(arylamino)aryl compounds | ASTELLAS PHARMA INC. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8318702-B2 | Di(arylamino)aryl compounds | ASTELLAS PHARMA INC. (JP) | 2012-11-27 | — | — | US | disclosed |
| CN-101687822-B | Di(arylamino)aryl compound | ASTELLAS PHARMA INC | 2012-11-07 | — | — | CN | disclosed |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-22 | — | — | US | disclosed |
| EP-2172461-A1 | DI(ARYLAMINO)ARYL COMPOUND | Astellas Pharma Inc. (JP) | 2010-04-07 | — | — | EP | disclosed |
| CN-101687822-A | Di(arylamino)aryl compound | ASTELLAS PHARMA INC | 2010-03-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096100-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | HPGD 4872/4885SIRT6 4245/4885MAPT 3344/4885 |
| US-20100099658-A1 | DI(ARYLAMINO)ARYL COMPOUND | ERBB4, EGFR, ALK | HPGD 4872/4885SIRT6 4245/4885MAPT 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.